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Case Report
INTRODUCTION
Immune mediated inner ear disease is occasionally associated 
with other systemic autoimmune diseases, such as rheumatoid 
arthritis and Wegener’s granulomatosis (1). Immunoglobulin G4 
(IgG4)-related systemic disease is proposed to describe systemic 
manifestation of autoimmune disease characterized by increased 
serum level of IgG4 and infiltration of IgG4 positive plasma cells 
in the involved organs, presenting pancreatitis, sclerosing chol-
angitis, retroperitoneal fibrosis, lymphadenitis, nephritis, inter-
stitial pneumonia, sialadenitis and prostatitis (2-4). We report on 
a patient who showed fluctuating mixed hearing loss as one of 
the initial manifestations of IgG4-related systemic disease, which 
has not been reported before.
CASE REPORT
A 66-years-old woman was referred from the neurology depart-
ment for bilateral tinnitus, hearing loss, and ear fullness that had 
progressed over the last two months. She also had headache, 
non-whirling type dizziness, left eyeball pain, arthralgia, and 
chronic cough. An otoscopic finding showed turbid ear drum in 
both ears. Four tone average of pure tone thresholds of the right 
ear were 43 dB (bone conduction) and 77 dB (air conduction), 
and those of the left ear 17 dB and 32 dB, respectively (Fig. 1, 
October 2008). Since follow-up audiometry after 2 weeks of 
treatment of antibiotics showed the disease to have worsened 
(Fig. 1, November 2008), myringotomy and a ventilation tube 
was inserted in the right ear. The ear drum and middle ear mu-
cosa was markedly edematous. Spontaneous nystagmus under 
Frenzel glasses was absent, but an alternating bithermal binaural 
caloric test showed complete canal paresis of the right side. The 
direction of nystagmus was not changed with ice water irriga-
tion from supine to prone position. Ophthalmologic examina-
tion showed no abnormality. Temporal bone computed tomogra-
phy (CT) showed partial haziness in the middle ear and mastoid 
space and thickening of the tympanic membrane and middle 
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ear mucosa. Brain magnetic resonance imaging (MRI) showed 
abnormal finding in pituitary fossa. It looks like mild pituitary 
gland enlargement or inflammatory haziness around pituitary 
fossa. Because of unilateral orbital pain and near the orbital 
apex lesion on MRI, neurologist suspected Tolosa-Hunt syn-
drome, and tried steroid therapy (prednisolone 60 mg per day 
for 25 days and then 30 mg per day for 15 days). During the 
steroid treatement, her right hearing improved (Fig. 1, Decem-
ber 2008). However, hearing loss was aggravated again (Fig. 1, 
February 2009) and left eyeball pain and cough relapsed about 
two months after steroid therapy. A chest CT was checked to 
evaluate cough, and it revealed multiple nodules in both lower 
lung fields and renal mass. Orbital CT revealed lacrimal gland 
enlargement. Biopsies of lacrimal gland, kidney and bronchial 
mucosa were preformed. Light microscopic examination showed 
dense lymphoplasma cell infiltration in the lacrimal gland, kid-
ney and bronchial mucosa. Immunostaining for IgG4 showed 
strong immunoreactivity for IgG4 in infiltrating lymphocytes 
and plasma cells (Fig. 2). Serologic tests revealed elevated serum 
IgG of 19.20 g/L (normal range, 3.65 to 9.41 g/L) and elevated 
serum IgG4 of 2.45 g/L (normal range, 0.061 to 1.1214 g/L). 
Based on multiple organ involvement, elevated serum level of 
IgG4, and infiltration of IgG4 positive cells in the pathologic 
findings, we could diagnose IgG4 related systemic disease. We 
started immunosuppressive treatments consist of methylpred-
nisolone at 60 mg per day and methotrexate at 12.5 mg per 
week, and her general condition and hearing markedly im-
proved (Fig. 1, March 2009). 
  Under maintenance immunosuppressive therapy (predniso-
lone at 25 mg per day and methotrexate at 15 mg per week), 
there was further improvement of air-bone gap as well as bone 
conduction threshold (Fig. 1, May 2009). The dose of predniso-
lone was gradually tapered and she has been treated with 5 mg 
daily without further symptoms. We received Seoul National 
University Hospital Institutional Review Board approval for this 
study. 
DISCUSSION
The concept of IgG4-related systemic disease has been recog-
nized recently. This disease is known that it involves various or-
gan and can be diagnosed by elevated serum IgG4 level and in-
filtration of IgG4 positive cells in the involved organs. Since Ha-
mano reported high serum IgG4 concentrations in patients with 
autoimmune pancreatitis (5), many authors reported multiple 
organ disease with hypergammaglobulinemia (3, 4). But this is 
the first report of otologic involvement.
  An autoimmune mechanism is assumed in patients with bilat-
eral progressive or fluctuating mixed hearing loss, especially 
when they respond to immunosuppressive treatment. Similar 
clinical characteristics were also found in the described patient 
with IgG4-related systemic disease, which suggests the inner ear 
can be the target of this systemic autoimmune disease. In addi-
tion, the severity of air-bone gap parallels the severity of senso-
rineural hearing loss, and fluctuates according to the course of 
immunosuppressive therapy. Therefore, otitis media was a part 
of this systemic disease and reflecting that respiratory epitheli-
um including middle ear mucosa can be the target in IgG4-relat-
ed systemic disease. Vestibular dysfunction may progress slowly, 
hence the patient’s dizziness was non-whirling nature without 
definite history of vertigo or imbalance.
  Treatment of this disease is immunosuppressive therapy (2-4). 
Oral prednisolone is usually started at 30-60 mg/day, and then it 
is tapered by 5 mg every 1-2 week. Serological and imaging 
tests are followed periodically after commencement of steroid 
therapy. Continued maintenance therapy with prednisolone 5 
mg/day is sometimes required to prevent relapse without com-
plete discontinuation of steroids (3, 4). In cases of autoimmune 
inner ear disease, maintenance dose is continued for a variable 
time but the patients with treatment duration of fewer than 6 
months are at increased risk of relapse compared with those 
Fig. 2. Immunoglobulin G4 (IgG4) immunoreactivity in lacrimal 
gland. Note strong immunoreactivity for IgG4 in the cytoplasm of in-
filtrated lymphocytes and plasma cells (×400).
Fig. 1. Change of hearing according to the immunosuppressive 
treatment. Black bars at the top indicate the period of immunosup-
pressive therapy.
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treated for 6 months or longer. Immunosuppressant such as 
methotrexate can be used for recurrent disease (6).
  IgG4-related systemic disease is an emerging clinical entity, 
involving diverse organs and systems including the middle ear 
and the inner ear. The disease was responsive to immunosup-
pressive treatment. 
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